Peritoneal fibrosing syndrome: Pathogenetic mechanism and current therapeutic strategies

Journal of the Chinese Medical Association

Volumn 68, Issue 9, 2005, Pages 401-405

  Hung, Kuan Yu ^a,b   Huang, Jenq Wen ^b   Tsai, Tun Jun ^b   Hsieh, Bor Shen ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cyclic AMP; Dipyridamole; Fibrosis; Mesothelial cell; Pentoxifylline

Indexed keywords

CYTOKINE; DIALYSIS FLUID; DIPYRIDAMOLE; GLUCOCORTICOID; GLUCOSE; PENTOXIFYLLINE; TAMOXIFEN;

BIOCOMPATIBILITY; DRUG MECHANISM; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LONG TERM CARE; MESOTHELIUM CELL; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PATIENT CARE; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSING SYNDROME; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; TISSUE DISTRIBUTION;

EID: 25444484710     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70154-6     Document Type: Review

References (43)

1. Mendelssohn DC. Peritoneal dialysis and the future: the role of peritoneal dialysis in the overall management of end-stage renal disease. Blood Purif 2003;21:20-8.
2. Van Bissen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000;11:116-25.
3. Davies SJ, Phillips L, Griffiths AM, Russell RH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998;54:2207-17.
4. Hung KY, Lin TJ, Tsai TJ, Chen WY. Impact of peritoneal membrane transport on technique failure and patient survival in a population on automated peritoneal dialysis. ASAIO J 1999;45:568-73.
5. Hung KY, Shyu RS, Huang JW, Tsai TJ, Chen WY. Natural changes in peritoneal equilibrium test results in CAPD patients: a retrospective, seven-year cohort survey. Artif Organs 2000; 24:261-4.
6. Williams JD, Craig KJ, Topley N, Williams GT. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int 2003; 63(Suppl):158-61.
7. Hung KY, Tsai TJ, Chen WY. Peritoneal fibrosis and its prevention. Nephrology 2002;7:227-32.
8. Kawaguchi Y, Kawaguchi H, Mujais S. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. Perit Dial Int 2000;20(Suppl):43-55.
9. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, et al. Morphologic changes in the peritoneal membrane of patients with renal failure. J Am Soc Nephrol 2002;13:470-9.
10. Nomoto Y, Kawaguchi Y, Kubo H. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
11. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998;13:541-9.
12. Hung KY, Shyu RS, Fang CC, Tsai CC, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int 2001;59:2316-24.
13. Stoenoiu MS, De Vrises AS, Brouet A, Moulin P, Feron O, Lameire N, Devuyst O. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002;62:668-78.
14. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:721-32.
15. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002;61:375-86.
16. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23: 530-41.
17. Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int 2003;(Suppl):57-74.
18. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17(Suppl):12-5.
19. Imai H, Nakamoto H, Fucshima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002;18:124-30.
20. del Peso S, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, Castro MJ, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndrome. Adv Perit Dial 2003;19:32-5.
21. Hekking LH, Harvey VS, Havenith CE, van den Born J, Beelen RH, Jackman BW, Nagy JA. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis. Perit Dial Int 2003;23:323-30.
22. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:721-8.
23. Hoff CM, Shockley TR. Peritoneal dialysis in the 21st century: the potential of gene therapy. J Am Soc Nephrol 2002;13(Suppl): 117-24.
24. Gey DC, Lesho EP, Manngold J. Management of peripheral arterial disease. Am Fam Physician 2004;69:525-30.
25. Shichiri M, Hirata Y. Regulation of cell growth and apoptosis by adrenomedullin. Hypert Res 2003;(Suppl):9-14.
26. Hewiston TD, Martic M, Darby IA, Kelynack KJ, Bisucci T, Tait MG, Becker GJ. Intracellular cyclic nucleotide analogues inhibit in vitro mitogenesis and activation of fibroblasts derived from obstructed rat kidneys. Nephron Exp Nephrol 2004;96:59-66.
27. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995; 70:91-9.
28. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 1999;56:932-43.
29. Fang CC, Yen CJ, Shyu RS, Wu MS, Tsai TJ, Hsieh BS. Pharmacologic agents inhibit rat mesangial cell proliferation and collagen synthesis. J Formos Med Assoc 1998;97:458-64.
30. Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxifylline inhibits PDGF-induced proliferation and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31:773-83.
31. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC. PPAR gamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003;64:52-62.
32. Kawano H, Kim S, Ohta K, Nakao T, Miyazaki H, Nakatani T, Iwao H. Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced mesangial cell proliferation and gene expression. J Am Soc Nephrol 2003;14:584-92.
33. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64.
34. Tsuchida K, Zhu Y, Siva S, Dunn SP, Sharma K. Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int 2003;63:2000-9.
35. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003;63:2010-9.
36. Haneda M, Araki SI, Sugimoto T, Togawa M, Koya D, Kikkawa R. Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotides. Kidney Int 1996;50:384-91.
37. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999;13: 1774-86.
38. Fang CC, Yen CJ, Chen YM, Shyu RS, Tsai TJ, Lee PH, Hsieh BS. Pentoxifylline inhibits human peritoneal mesothelial cell growth and collagen synthesis: effects on TGF-beta. Kidney Int 2000;57:2626-33.
39. Hung KY, Shyu RS, Fang CC, Tsai CC, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int 2001;59:2316-24.
40. Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney Int 2001;60:872-81.
41. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001;60:1249-57.
42. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ. Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003;18:670-6.
43. Fang CC, Lai MN, Chien CT, Hung KY, Tsai CC, Tsai TJ, Hsieh BS. Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis. Perit Dial Int 2003;23: 228-36.